Genta Receives Special Protocol Assessment From FDA For Randomized Trial Of Genasense(R) Plus Chemotherapy In Chronic Lymphocytic Leukemia

Sat, 07 Oct 2006 12:00 PM EST

... Genta Incorporated (Nasdaq: GNTA) announced that the Company's proposal for a randomized trial of Genasense(R) (oblimersen sodium) Injection in patients with chronic lymphocytic leukemia (CLL) has completed Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA). [click link for full article] ...